Lixte adds Northwestern's Lurie Cancer Center as second site for LB-100 + Dostarlimab trial in ovarian clear cell cancer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.
First patient dosed at Lurie; patient recruitment is underway. Lead investigator: Dr. Emily M. Hinchcliff.
Trial originally began in January 2024 at MD Anderson Cancer Center; lead investigator Dr. Amir Jazaeri.
Trial targets ovarian clear cell carcinoma, a disease with high unmet medical need.
LIXTE's proprietary compound LB-100 is combined with immunotherapy to enhance effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.